GRIT and Quangang announce IL-2 T-cell therapy partnership

2024-06-03
Pharmaceutical Technology
细胞疗法临床2期并购基因疗法免疫疗法
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
来源: Pharmaceutical Technology
The companies will produce a domestically manufactured alternative to the immune-regulating cytokine IL-2 in T-cell therapy. Credit: Anusorn Nakdee/Shutterstock.com.
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
来源: Pharmaceutical Technology
Clinical-stage cell therapy company Shanghai Grit Biotechnology (GRIT) has formed a strategic partnership with Quangang Pharmaceutical (Quangang) to enhance research and development in T-cell therapy for solid tumour patients in China.
Recommended Buyer's Guides
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
来源: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Compliance Software for the Pharmaceutical Industry
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
来源: Pharmaceutical Technology
Buyer's Guide
Top Guide for Cleanrooms and Cleanroom Flooring
The partnership’s primary goal is to develop a globally standardised IL-2 for solid tumour patients undergoing T-cell therapy.
It will focus on localising this standard with affordable pricing for Chinese patients.
The collaboration will concentrate on broadening the indications of Quanqi (125SER) Interleukin-2 (IL-2) products for solid tumours.
See Also:MSD agrees to acquire EyeBio for up to $3bn
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
来源: Pharmaceutical Technology
Merck introduces sterility testing solution for pharma quality control
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
来源: Pharmaceutical Technology
The partnership aims to produce a domestically manufactured alternative to the globally acknowledged immune-regulating cytokine IL-2 in T-cell therapy.
GRIT plans to utilise its extensive experience in T-cell therapy to accelerate the development and commercialisation of cell therapy products through the collaboration.
Both GRIT and Quangang believe that their joint efforts will soon enable a broader range of Chinese patients to access advanced and effective T-cell treatments, along with an affordable local IL-2 product.
GRIT’s non-gene-engineered tumour infiltrating lymphocytes (TILs) programme, GT101, is in a Phase II (pivotal) trial with plans for a biologics licence application (BLA) filing by 2025.
In 2023 Grit secured more than $60m (436.72m yuan) in a Series B funding round to support the development of its pipeline programmes.
China International Capital Corporation led the financing round, which saw investments from Qianhai Ark, Liando Group, Yuanhe Capital and HeFangTian Venture Partnership.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
GRIT and Quangang announce IL-2 T-cell therapy partnership
Preview
来源: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。